Federal Register / Vol. 89, No. 23 / Friday, February 2, 2024 / Notices 7401 

provide home visiting services to 

eligible families in at-risk communities. 

Through the Home Visiting 

Assessment of Implementation Quality 

study, HRSA aims to examine specific 

components of the Home Visiting 

Implementation Quality Conceptual 

Framework to inform strategies for 

implementing high quality home 

visiting programs. One of the three 

quality components the study will focus 

on is support for supervisors of home 

visitors. A qualified, stable, and 

supported home visitor workforce is an 

important quality component of home 

visiting, and supervision is a key part of 

supporting that workforce. The 

requested information collection will 

explore how training for supervisors 

may be linked to home visitor job 

satisfaction. It will also examine how 

supervisor training in important content 

areas (e.g., substance use, intimate 

partner violence) may affect the extent 

to which home visitors talk to families 

about these topics. Data collection will 

include an online recruitment survey, 

interviews, and focus groups. 

Need and Proposed Use of the 

Information: HRSA is seeking additional 

information about how the MIECHV 

Program can train and support 

supervisors of home visitors to provide 

high-quality supervision. HRSA intends 

to use this information to identify 

practices that MIECHV awardees and 

LIAs could use to best support home 

visiting supervisors, improving home 

visitors’ ability to deliver high-quality 

home visiting services. 

Likely Respondents: MIECHV-funded 

LIA staff, including program directors, 

coordinators, supervisors, and home 

visitors. 

Burden Statement: Burden in this 

context means the time expended by 

persons to generate, maintain, retain, 

disclose, or provide the information 

requested. This includes the time 

needed to review instructions; to 

develop, acquire, install, and utilize 

technology and systems for the purpose 

of collecting, validating, and verifying 

information, processing and 

maintaining information, and disclosing 

and providing information; to train 

personnel and to be able to respond to 

a collection of information; to search 

data sources; to complete and review 

the collection of information; and to 

transmit or otherwise disclose the 

information. The total annual burden 

hours estimated for this ICR are 

summarized in the table below. 

TOTAL ESTIMATED ANNUALIZED BURDEN HOURS

Form name Number of 

respondents 

Number of 

responses per 

respondent 

Total 

responses 

Average 

burden per 

response 

(in hours) 

Total burden 

hours 

Recruitment Survey ............................................................. 250 1 250 0.17 42.5 

LIA Program Director Interview Guide ................................. 50 1 50 1.00 50.0 

Supervisor Focus Group Protocol ....................................... 50 1 50 1.50 75.0 

Home Visitor Focus Group Protocol .................................... 50 1 50 1.50 75.0 

Total .............................................................................. 400 ........................ 400 ........................ 242.5 

HRSA specifically requests comments 

on (1) the necessity and utility of the 

proposed information collection for the 

proper performance of the agency’s 

functions, (2) the accuracy of the 

estimated burden, (3) ways to enhance 

the quality, utility, and clarity of the 

information to be collected, and (4) the 

use of automated collection techniques 

or other forms of information 

technology to minimize the information 

collection burden. 

Maria G. Button, 

Director, Executive Secretariat. 

[FR Doc. 2024–02096 Filed 2–1–24; 8:45 am] 

BILLING CODE 4165–15–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Center for Scientific Review; Notice of 

Closed Meetings 

Pursuant to section 1009 of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Member 

Conflict: Topics in Autoimmunity, 

Immunology and Transplantation. 

Date: February 28, 2024. 

Time: 9:00 a.m. to 8:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892. 

Contact Person: Shannon J. Sherman, 

Ph.D., Scientific Review Officer, The Center 

for Scientific Review, The National Institutes 

of Health, 6701 Rockledge Drive, Bethesda, 

MD 20892, 301–594–0715, 

shannon.sherman@nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Advancing 

Therapeutics. 

Date: February 28–29, 2024. 

Time: 9:00 a.m. to 7:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Gaithersburg Marriott 

Washingtonian Center, 9751 Washingtonian 

Blvd., Gaithersburg, MD 20878. 

Contact Person: Lystranne Alysia Maynard 

Smith, Ph.D., Scientific Review Officer, 

Center for Scientific Review, National 

Institutes of Health, 6701 Rockledge Drive, 

Bethesda, MD 20892, 301–402–4809, 

lystranne.maynard-smith@nih.gov. 

Name of Committee: Healthcare Delivery 

and Methodologies Integrated Review Group; 

Healthcare and Health Disparities Study 

Section. 

Date: February 28–29, 2024. 

Time: 9:00 a.m. to 6:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892. 

Contact Person: Tara Roshell Earl, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 1007C, 

Bethesda, MD 20892, (301) 402–6857, earltr@

mail.nih.gov. 

Name of Committee: Bioengineering 

Sciences & Technologies Integrated Review 

Group; Modeling and Analysis of Biological 

Systems Study Section. 

Date: February 29–March 1, 2024. 

Time: 8:00 a.m. to 6:30 p.m. 


khammond on DSKJM1Z7X2PROD with NOTICES
7402 Federal Register / Vol. 89, No. 23 / Friday, February 2, 2024 / Notices 

Agenda: To review and evaluate grant 

applications. 

Place: North Bethesda Marriott Hotel & 

Conference Center, Montgomery County 

Conference Center Facility, 5701 Marinelli 

Road, North Bethesda, MD 20852. 

Contact Person: Zarana Patel, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Bethesda, MD 

20892, (301) 496–9295, zarana.patel@

nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; 

Fellowships: Cell Biology, Developmental 

Biology, and Bioengineering. 

Date: February 29–March 1, 2024. 

Time: 8:30 a.m. to 7:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892. 

Contact Person: Mufeng Li, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Bethesda, MD 

20892, (301) 435–5653, limuf@nih.gov. 

Name of Committee: Infectious Diseases 

and Immunology A Integrated Review Group; 

Cellular and Molecular Immunology—B 

Study Section. 

Date: February 29–March 1, 2024. 

Time: 9:00 a.m. to 7:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892. 

Contact Person: Liying Guo, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 4198, 

MSC 7812, Bethesda, MD 20892, (301) 827– 

7728, lguo@mail.nih.gov. 

Name of Committee: Healthcare Delivery 

and Methodologies Integrated Review Group; 

Organization and Delivery of Health Services 

Study Section. 

Date: February 29–March 1, 2024. 

Time: 9:00 a.m. to 6:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892. 

Contact Person: Catherine Hadeler 

Maulsby, MPH, Ph.D., Scientific Review 

Officer, Center for Scientific Review, 

National Institutes of Health, 6701 Rockledge 

Drive, Bethesda, MD 20892, (301) 435–1266, 

maulsbych@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; 

Fellowships: Biophysical, Physiological, 

Pharmacological and Bioengineering 

Neuroscience, and Vision. 

Date: February 29–March 1, 2024. 

Time: 9:00 a.m. to 7:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892. 

Contact Person: Jennifer Kielczewski, 

Ph.D., Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Bethesda, MD 

20892, (301) 435–1042, jennifer.kielczewski@

nih.gov. 

Name of Committee: Applied Immunology 

and Disease Control Integrated Review 

Group; Vaccines Against Infectious Diseases 

Study Section. 

Date: February 29–March 1, 2024. 

Time: 9:00 a.m. to 7:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892. 

Contact Person: Jian Wang, Ph.D., MD, 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 4218, 

MSC 7812, Bethesda, MD 20892, (301) 213– 

9853, wangjia@csr.nih.gov. 

Name of Committee: Oncology 2— 

Translational Clinical Integrated Review 

Group; Therapeutic Immune Regulation 

Study Section. 

Date: February 29–March 1, 2024. 

Time: 9:00 a.m. to 7:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892. 

Contact Person: Yue Wu, Ph.D., Scientific 

Review Officer, Center for Scientific Review, 

National Institutes of Health, 6701 Rockledge 

Drive, Room 803C, Bethesda, MD 20892, 

(301) 867–5309, wuy25@csr.nih.gov. 

Name of Committee: Infectious Diseases 

and Immunology B Integrated Review Group; 

Etiology, Diagnostic, Intervention and 

Treatment of Infectious Diseases Study 

Section. 

Date: February 29–March 1, 2024. 

Time: 9:30 a.m. to 8:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892. 

Contact Person: Liangbiao Zheng, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 3202, 

MSC 7808, Bethesda, MD 20892, (301) 996– 

5819, zhengli@csr.nih.gov. 

Name of Committee: Cell Biology 

Integrated Review Group; Maximizing 

Investigators’ Research Award C Study 

Section. 

Date: February 29–March 1, 2024. 

Time: 10:00 a.m. to 8:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892. 

Contact Person: Jimok Kim, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Bethesda, MD 

20892, (301) 402–8559, jimok.kim@nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; 

Fellowships: Genes, Genomes and Genetics. 

Date: February 29–March 1, 2024. 

Time: 10:00 a.m. to 8:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892. 

Contact Person: Linda Wagner Jurata, 

Scientific Review Officer, The Center for 

Scientific Review, The National Institutes of 

Health, 6701 Rockledge Drive, Bethesda, MD 

20892, (301) 496–8032, linda.jurata@nih.gov. 

Name of Committee: Infectious Diseases 

and Immunology A Integrated Review Group; 

Innate Immunity and Inflammation Study 

Section. 

Date: February 29–March 1, 2024. 

Time: 10:00 a.m. to 8:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892. 

Contact Person: Bakary Drammeh, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 805–P, 

Bethesda, MD 20892, (301) 435–0000, 

drammehbs@csr.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.306, Comparative Medicine; 

93.333, Clinical Research, 93.306, 93.333, 

93.337, 93.393–93.396, 93.837–93.844, 

93.846–93.878, 93.892, 93.893, National 

Institutes of Health, HHS) 

Dated: January 29, 2024. 

Lauren A. Fleck, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2024–02047 Filed 2–1–24; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute on Minority Health 

and Health Disparities; Notice of 

Closed Meeting 

Pursuant to section 1009 of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute on 

Minority Health and Health Disparities 

Special Emphasis Panel; Interventions to 

Address HIV-Related Comorbidities among 


khammond on DSKJM1Z7X2PROD with NOTICES